High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

NCT06319950 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

255

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer, Nonsmall Cell

Interventions

DRUG: Furmonertinib
DRUG: Osimertinib

Sponsor

Taizhou Hospital